ISRAEL AT WAR - DAY 144

search

Ichilov first hospital outside US to treat Alzheimer’s patients with new drug Lecanemab

Renee Ghert-Zand is the health reporter and a feature writer for The Times of Israel.

Patient Ophira Barkan with Dr Noa Bergman (center) and Dr Tamara Shiner  at Ichilov Hospital, which becomes the first outside of the US authorized to administer new Alzheimer’s drug Lecanemab in a photo released December 7, 2023 (Jenny Yerushalmi/Ichilov)
Patient Ophira Barkan with Dr Noa Bergman (center) and Dr Tamara Shiner at Ichilov Hospital, which becomes the first outside of the US authorized to administer new Alzheimer’s drug Lecanemab in a photo released December 7, 2023 (Jenny Yerushalmi/Ichilov)

Ichilov Hospital announces that this week it began treating patients with Alzheimer’s drug Lecanemab.

Ichilov is the only medical center outside the United States authorized by drugmaker Eisai to administer the medication, which is newly approved by the US Food and Drug Administration.

The medication, sold under the brand name Leqembi, is produced by the Japanese company Eisai and its US partner Biogen.

Leqembi is an antibody intravenous infusion therapy that targets and removes beta-amyloid plaques from the brain. The FDA approved its use in treating early Alzheimer’s disease, including people living with mild cognitive impairment or mild dementia due to Alzheimer’s disease who have confirmation of elevated beta-amyloid in the brain.

Dr. Tamara Shiner, a neurology specialist and head of Ichilov’s service for frontal neurological syndromes and dementia with Lewy bodies, says that the hospital has set up a system to identify patients with early-stage Alzheimer’s who could benefit from this treatment.

Among the first Israelis to receive a Leqembi infusion this week is 76-year-old Ophira Barkan.

“I am very excited to be among the first patients to get this medication. I hold out a lot of hope for it. This is the first time that there is a drug to treat Alzheimer’s and it’s providing me some light,” she says.

Never miss breaking news on Israel
Get notifications to stay updated
You're subscribed
image
Register for free
and continue reading
Registering also lets you comment on articles and helps us improve your experience. It takes just a few seconds.
Already registered? Enter your email to sign in.
Please use the following structure: example@domain.com
Or Continue with
By registering you agree to the terms and conditions. Once registered, you’ll receive our Daily Edition email for free.
Register to continue
Or Continue with
Log in to continue
Sign in or Register
Or Continue with
check your email
Check your email
We sent an email to you at .
It has a link that will sign you in.